László Vécsei

Q: What Schools Are Affiliated With László Vécsei

László Vécsei is affiliated with the following schools: Yale University, University of Szeged

László Vécsei's AcademicInfluence.com Rankings

László Vécsei

Medical

#1870

World Rank

#2249

Historical Rank

Neurology

#174

World Rank

#243

Historical Rank

medical Degrees

Download Badge

Medical

László Vécsei's Degrees

Doctorate Medicine University of Szeged
PhD Neurology University of Szeged

Why Is László Vécsei Influential?

(Suggest an Edit or Addition)

(See a Problem?)

László Vécsei's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The epidemiology of multiple sclerosis in Europe (2006) (609)
Kynurenines in the CNS: recent advances and new questions (2012) (490)
Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders (2007) (462)
The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study (2017) (341)
EFNS guideline on mild traumatic brain injury: report of an EFNS task force (2002) (333)
The kynurenine system and immunoregulation (2012) (322)
Mild traumatic brain injury (2012) (261)
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study (2015) (255)
Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients (2013) (161)
Role of kynurenines in the central and peripheral nervous systems. (2005) (151)
Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis (2000) (140)
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial (2018) (136)
Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection (2018) (129)
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines (2020) (120)
Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain (1992) (115)
The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection (2009) (112)
Monoamine Oxidase B Inhibitors in Parkinson's Disease. (2017) (108)
The Janus-face kynurenic acid (2008) (104)
Migraine and neuropeptides (2015) (104)
Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway (2021) (101)
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease (2011) (96)
Neurofilament ELISA validation. (2010) (90)
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease (2009) (88)
Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. (2006) (88)
Opposite action of oxytocin to vasopressin in passive avoidance behavior in rats (1978) (87)
Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis (2011) (86)
Carotid stenosis and the cognitive function (2009) (86)
White matter microstructural alterations in migraine: A diffusion-weighted MRI study (2012) (86)
Release of PACAP-38 in episodic cluster headache patients – an exploratory study (2016) (84)
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial (2019) (83)
Familial effects on the clinical course of multiple sclerosis (2006) (82)
Nonenzymatic antioxidants of blood in multiple sclerosis (1999) (81)
Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders (2012) (81)
Effect of systemic nitroglycerin on CGRP and 5‐HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen (2002) (81)
Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies (2009) (81)
Comparative studies with somatostatin and cysteamine in different behavioral tests on rats (1984) (80)
Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs (2007) (78)
Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease (2005) (75)
Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. (2007) (75)
Huntington’s disease: pathomechanism and therapeutic perspectives (2004) (73)
Therapeutic Approaches for Peripheral and Central Neuropathic Pain (2019) (73)
N‐Methyl‐d‐aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat (2010) (73)
Large motor units are selectively affected following a stroke (2008) (73)
The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: Comparative studies of the effects of SZR-72 and kynurenic acid (2008) (69)
The Hungarian validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery and the correlation of cognitive impairment with fatigue and quality of life. (2015) (69)
Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway (2020) (69)
Ischemic heart disease induce upregulation of endothelin receptor mRNA in human coronary arteries. (2004) (68)
Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. (2018) (68)
The diabetic brain and cognition (2017) (67)
Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system (2012) (66)
Evidence-based pharmacological treatment of neuropathic pain syndromes (2005) (66)
Increased glucose metabolism and ATP level in brain tissue of Huntington’s disease transgenic mice (2008) (66)
The involvement of catecholaminergic mechanisms in the behavioural action of vasopressin (1977) (65)
Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils (2011) (65)
PACAP and its role in primary headaches (2018) (65)
Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. (2014) (64)
Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update (2015) (64)
Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations (2015) (61)
l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus (2009) (61)
Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache (1995) (60)
Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c‐fos in the caudal trigeminal nucleus in an experimental migraine model (1997) (59)
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease (2018) (58)
Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach (2011) (57)
Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. (2012) (57)
Intracerebroventricular somatostatin attenuates electroconvulsive shock-induced amnesia in rats (1983) (57)
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines (2011) (57)
Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians (2013) (56)
Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism (2020) (56)
Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. (2011) (56)
Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity (2013) (54)
Kynurenines, neurodegeneration and Alzheimer’s disease (2010) (54)
The effects of reward and punishment contingencies on decision-making in multiple sclerosis (2006) (53)
Comparative behavioral and neurochemical studies with striatal kainic acid- or quinolinic acid-lesioned rats (1991) (52)
Dural administration of inflammatory soup or Complete Freund’s Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion (2015) (51)
Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study (2004) (51)
Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model (2006) (51)
Interictal brain activity differs in migraine with and without aura: resting state fMRI study (2017) (50)
Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat (2012) (50)
Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment (2004) (49)
Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion (2015) (49)
Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophan–Kynurenine Metabolic System (2022) (48)
Kynurenate Derivative Attenuates the Nitroglycerin‐Induced CamKIIα and CGRP Expression Changes (2009) (48)
The Prevalence of Multiple Sclerosis, Distribution of Clinical Forms of the Disease and Functional Status of Patients in Csongrád County, Hungary (2001) (48)
Kynurenines and intestinal neurotransmission: the role of N-methyl-d-aspartate receptors (2012) (48)
[Nature Reviews Drug Discovery: editorial article of neuroscientists from Szeged about kynurenine (IF: 33.078)]. (2014) (47)
Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus (2008) (47)
Migraine is a neuronal disease (2011) (47)
Cortical and Subcortical Atrophy in Alzheimer Disease: Parallel Atrophy of Thalamus and Hippocampus (2014) (46)
Male brain ages faster: the age and gender dependence of subcortical volumes (2016) (46)
A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study (2010) (45)
Calcitonin gene-related peptide levels in saliva of patients with burning mouth syndrome. (2008) (45)
Aspirin resistance in stroke: 2004 (2005) (44)
Monitoring the Redox Status in Multiple Sclerosis (2020) (44)
Valproate Treatment and Platelet Function: The Role of Arachidonate Metabolites (1999) (44)
Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c‐fos and c‐jun in the trigeminal complex of the rat in an experimental migraine model (2000) (44)
Opposite effects of centrally administered neuropeptide Y (NPY) on locomotor activity of spontaneously hypertensive (SH) and normal rats. (1989) (44)
Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study (2019) (43)
Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis (2017) (43)
Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood–brain barrier permeability (2013) (43)
Drug safety and tolerability in prophylactic migraine treatment (2015) (43)
Editorial of Special Issue “Crosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry” (2021) (43)
Interferon‐β affects the tryptophan metabolism in multiple sclerosis patients (2005) (42)
N-methyl-D-aspartate receptor antagonist therapy suppresses colon motility and inflammatory activation six days after the onset of experimental colitis in rats. (2012) (41)
Changes in muscle fiber density following a stroke (2009) (41)
Favorable Early Outcome of Carotid Artery Stenting Without Protection Devices (2004) (41)
Gray Matter Is Targeted in First-Attack Multiple Sclerosis (2013) (41)
Neurology residency training in Europe – the current situation (2011) (41)
Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. (2010) (41)
Spatial Contrast Sensitivity of Migraine Patients Without Aura (2002) (40)
Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. (2015) (40)
Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene-related peptide via activation of extracellular signal-regulated protein kinase 1/2 (2011) (40)
Nitroglycerin-Induced nNOS Increase in Rat Trigeminal Nucleus Caudalis is Inhibited by Systemic Administration of Lysine Acetylsalicylate but not of Sumatriptan (2004) (39)
Oxaloacetate restores the long-term potentiation impaired in rat hippocampus CA1 region by 2-vessel occlusion. (2009) (39)
Monitoring the kynurenine system: Concentrations, ratios or what else? (2021) (39)
Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. (1991) (39)
Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects. (2017) (38)
Preclinical and clinical studies with somatostatin related to the central nervous system (1990) (38)
Amino Acids in the Saliva of Patients With Migraine (1999) (38)
Effects of in vivo sodium azide administration on the immunohistochemical localization of kynurenine aminotransferase in the rat brain (1999) (38)
Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases. (2018) (37)
Evidence for Plastic Processes in Migraine with Aura: A Diffusion Weighted MRI Study (2018) (37)
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms (2017) (37)
Antidepressant-like effects of kynurenic acid in a modified forced swim test (2020) (37)
The modulatory effect of anandamide on nitroglycerin-induced sensitization in the trigeminal system of the rat (2016) (37)
Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate. (2008) (37)
α-Tocopherol/lipid ratio in blood is decreased in patients with Leber's hereditary optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutation (2001) (37)
Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease (2020) (37)
A pilot study on the antibodies to HHV-6 variants and HHV-7 in CSF of MS patients. (1999) (36)
Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater (1999) (36)
Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. (2002) (36)
Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats (1990) (36)
Effects of intracerebroventricularly administered somatostatin on passive avoidance, shuttle-box behaviour and open-field activity in rats (1988) (36)
Kynurenines in neurodegenerative disorders: therapeutic consideration. (2004) (36)
Kynurenines in Parkinson’s disease: therapeutic perspectives (2012) (36)
Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra (2006) (36)
Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion (2004) (35)
Hippocampal (CA1) activities in Wistar rats from different vendors Fundamental differences in acute ischemia (2006) (35)
Stroke in essential thrombocythemia (2014) (35)
Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study. (2017) (35)
Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission (2022) (35)
Oestrogen-Modulated Increase of Calmodulin-Dependent Protein Kinase II (CamKII) in Rat Spinal Trigeminal Nucleus After Systemic Nitroglycerin (2007) (34)
Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research (2021) (34)
Language deficits in pre-symptomatic Huntington’s disease: Evidence from Hungarian (2012) (34)
Ischemic heart disease induces upregulation of endothelin receptor mRNA in human coronary arteries. (2004) (34)
Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid (2007) (34)
Chronic infections and genetic factors in the development of ischemic stroke. (2007) (33)
Clinical Efficacy of a Single Afternoon Dose of Effervescent Levodopa-Carbidopa Preparation (CHF 1512) in Fluctuating Parkinson Disease (2007) (33)
Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats (1990) (33)
Selegiline: a molecule with innovative potential (2019) (33)
Oxaloacetate Decreases the Infarct Size and Attenuates the Reduction in Evoked Responses after Photothrombotic Focal Ischemia in the Rat Cortex (2009) (33)
Eculizumab improves fatigue in refractory generalized myasthenia gravis (2019) (32)
Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness An overview (1988) (32)
CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes. (2000) (32)
Kynurenines and headache (2012) (32)
Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection (2011) (32)
Depletion of calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat after electrical stimulation of the Gasserian ganglion (1998) (32)
Prevalence of multiple sclerosis in Csongrád County, Hungary (2014) (31)
The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets. (2000) (31)
Suboccipital cerebrospinal fluid and plasma concentrations of somatostatin, neuropeptide Y and beta-endorphin in patients with common migraine (1992) (31)
Comparative studies with cyclic and linear somatostatin on active avoidance behaviour and open-field activity in rats. (1983) (30)
Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System (2015) (30)
Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents—in celebration of 80th birthday of Professor Peter Riederer (2022) (30)
Target Identification for Stereotactic Thalamotomy Using Diffusion Tractography (2012) (30)
Memantine and Kynurenic Acid: Current Neuropharmacological Aspects (2016) (30)
Platelet arachidonate cascade of migraineurs in the interictal phase. (2000) (30)
Drug safety in acute migraine treatment (2015) (29)
Targeting of the kynurenic acid across the blood-brain barrier by core-shell nanoparticles. (2016) (29)
Co-Players in Chronic Pain: Neuroinflammation and the Tryptophan-Kynurenine Metabolic Pathway (2021) (29)
Synthesis and biological effects of some kynurenic acid analogs. (2011) (29)
Neuroprotection in Parkinson’s disease: facts and hopes (2019) (29)
Novel therapeutic strategies in Parkinson’s disease (2010) (29)
Complex hallucinations following occipital lobe damage (2002) (29)
[VALIDATION OF THE HUNGARIAN MDS-UPDRS: WHY DO WE NEED A NEW PARKINSON SCALE?]. (2014) (29)
The role of the putamen in cognitive functions — A case study (2009) (29)
Where does a migraine attack originate? In the brainstem (2012) (28)
Novel AARS2 gene mutation producing leukodystrophy: a case report (2016) (28)
Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice (2015) (28)
Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. (2005) (28)
White matter disintegration in cluster headache (2013) (28)
Proteomic Analysis of Cerebrospinal Fluid in a Fulminant Case of Multiple Sclerosis (2012) (28)
Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex (2014) (28)
The inimitable kynurenic acid: The roles of different ionotropic receptors in the action of kynurenic acid at a spinal level (2015) (28)
L-kynurenine: Metabolism and mechanism of neuroprotection (2008) (28)
Behavioural studies with a newly developed neuroprotective KYNA-amide (2012) (28)
Non-invasive Brain Stimulation in Alzheimer's Disease and Mild Cognitive Impairment—A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters (2020) (27)
Contributing factors to health‐related quality of life in multiple sclerosis (2019) (27)
Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives (2020) (27)
Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome. (2017) (27)
Effect of 3-Nitropropionic Acid on Kynurenine Aminotransferase in the Rat Brain (2002) (27)
AZ MDS-UPDRS MAGYAR VALIDÁCIÓJA: MIÉRT SZÜKSÉGES ÚJABB PARKINSON-PONTOZÓSKÁLA? (2014) (27)
Comparative study on the effects of kynurenic acid and glucosamine–kynurenic acid (2004) (27)
Kynurenine Metabolites and Migraine: Experimental Studies and Therapeutic Perspectives (2011) (27)
Role of PACAP in migraine headaches. (2014) (27)
Dementia, stroke and migraine — Some common pathological mechanisms (2010) (27)
Immunomodulatory Effects of Genetic Alterations Affecting the Kynurenine Pathway (2019) (27)
Behaviour changes in a transgenic model of Huntington's disease (2006) (26)
Somatostatin and cognitive function in neurodegenerative disorders. (2012) (26)
Evans Blue fluorescence permits the rapid visualization of non-intact cells in the perilesional rim of cold-injured rat brain. (2007) (26)
The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary. (2016) (26)
Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics (2015) (26)
Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72) (2017) (26)
Effects of centrally administered neuropeptide Y (NPY) and NPY13–36 on the brain monoaminergic systems of the rat (1990) (26)
Ethanol effects on bradykinin-stimulated phosphoinositide hydrolysis in NG 108-15 neuroblastoma-glioma cells. (1989) (25)
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications (2012) (25)
Selective inhibition of cyclooxygenase-2 attenuates nitroglycerin-induced calmodulin-dependent protein kinase II alpha in rat trigeminal nucleus caudalis (2009) (25)
Crosstalk between Existential Phenomenological Psychotherapy and Neurological Sciences in Mood and Anxiety Disorders (2021) (25)
Medical treatment of Parkinson's disease: today and the future. (2010) (25)
Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system (1990) (25)
cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases (2010) (25)
Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists (2011) (25)
Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety (2015) (24)
Cox‐2 Inhibitor Attenuates NO‐Induced nNOS in Rat Caudal Trigeminal Nucleus (2007) (24)
KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion (2016) (24)
Electrophysiological correlates of visual categorization: evidence for cognitive dysfunctions in early Parkinson's disease. (2002) (24)
Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis (2013) (24)
Are 5-HT1 receptor agonists effective anti-migraine drugs? (2021) (24)
A population‐based epidemiological study of neuromyelitis optica spectrum disorder in Hungary (2020) (24)
Effects of β-(Tyr9)melantropin-(9–18) decapeptide on passive and active avoidance behavior and on open-field activity of rats (1981) (24)
Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. (2011) (24)
Neuroprotective effects of probenecid in a transgenic animal model of Huntington’s disease (2009) (23)
Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism. (2016) (23)
Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid (2021) (23)
A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. (2011) (23)
Modifications on the carboxylic function of kynurenic acid (2012) (23)
Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy (2017) (23)
RAGE Gene Polymorphisms in Patients with Multiple Sclerosis (2009) (23)
The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients (2006) (23)
Evaluation of c-Fos immunoreactivity in the rat brainstem nuclei relevant in migraine pathogenesis after electrical stimulation of the trigeminal ganglion (2013) (23)
[Mechanism of cough syncope]. (2004) (22)
The Opposite Effects of Kynurenic Acid and Different Kynurenic Acid Analogs on Tumor Necrosis Factor-α (TNF-α) Production and Tumor Necrosis Factor-Stimulated Gene-6 (TSG-6) Expression (2019) (22)
Cross-cultural adaptation and validation of the `Multiple Sclerosis Quality of Life Instrument' in Hungarian (2008) (22)
Astrocytic and neuronal localization of kynurenine aminotransferase-2 in the adult mouse brain (2017) (22)
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab (2020) (22)
The potential role of kynurenines in Alzheimer’s disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors (2014) (22)
Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC (2018) (22)
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model (2001) (22)
Comparative studies of somatostatin-14 and some of its fragments on passive avoidance behavior, open field activity and on barrel rotation phenomenon in rats (1989) (22)
Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives (2010) (22)
The Contribution of Various MRI Parameters to Clinical and Cognitive Disability in Multiple Sclerosis (2019) (22)
Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson's Disease? (2014) (22)
Diagnostic yield of five minutes compared to three minutes hyperventilation during electroencephalography (2015) (21)
B7 costimulation and intracellular indoleamine-2,3-dioxygenase (IDO) expression in peripheral blood of healthy pregnant and non-pregnant women (2014) (21)
Continuous theta-burst stimulation over the dorsolateral prefrontal cortex inhibits improvement on a working memory task (2018) (21)
The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of l-kynurenine to kynurenic acid: An in vitro study (2008) (21)
Increased Dopamine Content in Lymphocytes from High-Dose L-Dopa-Treated Parkinson’s Disease Patients (2005) (21)
Temporal instability of salience network activity in migraine with aura. (2019) (21)
Somatostatin and (d-TRP8, d-CYS14)-somatostatin delay extinction and reverse electroconvulsive shock induced amnesia in rats (1986) (21)
Alzheimer's disease, astrocytes and kynurenines. (2015) (21)
Factors influencing the health-related quality of life in Hungarian multiple sclerosis patients (2010) (21)
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. (2006) (21)
Drug-induced movement disorders (2015) (21)
Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease (2015) (21)
Diclofenac Epolamine is Effective in The Treatment of Acute Migraine Attacks. A Randomized, Crossover, Double Blind, Placebo-Controlled, Clinical Study (2007) (20)
Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis (2020) (20)
Kynurenines and other novel therapeutic strategies in the treatment of dementia (2013) (20)
Epidemiology of familial multiple sclerosis in Hungary (2007) (20)
Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis (2017) (20)
Opicapone for the treatment of Parkinson’s disease: an update (2019) (20)
Validation of the Fatigue Impact Scale in Hungarian patients with multiple sclerosis (2011) (20)
Gray Matter Atrophy Is Primarily Related to Demyelination of Lesions in Multiple Sclerosis: A Diffusion Tensor Imaging MRI Study (2017) (20)
A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis. (2020) (20)
A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study (2012) (19)
Post-ischemic treatment with L-kynurenine sulfate exacerbates neuronal damage after transient middle cerebral artery occlusion (2013) (19)
Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner (2015) (19)
Molecular plasticity of primary nociceptive neurons: relations of the NGF-c-jun system to neurotomy and chronic pain. (2003) (19)
Neuroprotective Effect of Oxaloacetate in a Focal Brain Ischemic Model in the Rat (2014) (19)
Editorial of Special Issue ‘Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection’ (2022) (19)
Effect of Systemic Administration of L‐Kynurenine on Corticocerebral Blood Flow under Normal and Ischemic Conditions of the Brain in Conscious Rabbits (2003) (19)
Neuropathology of Partial PGC-1α Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases (2013) (19)
Are Migraine With and Without Aura Really Different Entities? (2019) (19)
Topical acetylsalicylic acid versus lidocaine for postherpetic neuralgia: results of a double-blind comparative clinical trial. (1999) (19)
Safinamide for the treatment of Parkinson's disease (2014) (19)
Long-term effects of neonatal MK-801 treatment on spatial learning and cortical plasticity in adult rats (2002) (19)
Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature (2018) (19)
Current medical aspects of pantethine. (2009) (19)
The rs13388259 Intergenic Polymorphism in the Genomic Context of the BCYRN1 Gene Is Associated with Parkinson's Disease in the Hungarian Population (2018) (18)
Basilar artery occlusion associated with anabolic steroid abuse in a 17-year-old bodybuilder. (1997) (18)
Distinct cytokine patterns may regulate the severity of neonatal asphyxia—an observational study (2017) (18)
Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial (2020) (18)
Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis—Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines (2019) (18)
An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson’s disease (2016) (18)
A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study (2016) (18)
Relevance of the genetic polymorphism of NOD1 in Chlamydia pneumoniae seropositive stroke patients (2009) (18)
Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. (2011) (18)
The Effect of Systemic Nitroglycerin Administration on the Kynurenine Pathway in the Rat (2017) (18)
CGRP antagonists and antibodies for the treatment of migraine (2015) (18)
Corticostriatal circuitry mediates fast-track visual categorization. (2002) (18)
A genome-wide screen for association in Hungarian multiple sclerosis (2003) (17)
Paradox effects of kynurenines on LTP induction in the Wistar rat. An in vivo study (2013) (17)
Huntington's disease, behavioral disturbances, and kynurenines: Preclinical findings and therapeutic perspectives (1996) (17)
Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period (2021) (17)
The effect of somatostatin, its fragments and an analog on electroconvulsive shock-induced amnesia in rats (1984) (17)
Analysis of CAG Repeat Expansion in Huntington’s Disease Gene (IT 15) in a Hungarian Population (1999) (17)
Action of Somatostatin on the Central Nervous System (1987) (17)
The L-kynurenine signalling pathway in trigeminal pain processing: A potential therapeutic target in migraine? (2011) (17)
Diminished blood levels of reduced glutathione and alpha-tocopherol in two triosephosphate isomerase-deficient brothers. (2000) (17)
The effect of somatostatin on self-stimulation behavior in atropine- and methysergide-pretreated rats. (1983) (17)
Neurotoxins and neurodegenerative disorders. (1998) (17)
Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease (2013) (17)
Kinetic and Thermodynamic Evaluation of Kynurenic Acid Binding to GluR1270-300 Polypeptide by Surface Plasmon Resonance Experiments. (2016) (17)
The effect of linear somatostatin on the active avoidance behaviour and open-field activity on haloperidol, phenoxybenzamine and atropine pretreated rats. (1983) (17)
Investigational α-synuclein aggregation inhibitors: hope for Parkinson’s disease (2016) (17)
Drug targets of migraine and neuropathy: treatment of hyperexcitability. (2015) (17)
Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression (2021) (16)
Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series (2017) (16)
Dopaminergic contributions to the visual categorization of natural scenes: evidence from Parkinson's disease (2003) (16)
The effect of somatostatin on the self-stimulation of rats (1982) (16)
Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. (2007) (16)
Altered Resting State Functional Activity and Microstructure of the White Matter in Migraine With Aura (2019) (16)
Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine (2017) (16)
The pattern of diffusion parameter changes in Alzheimer's disease, identified by means of linked independent component analysis. (2013) (16)
Novel Pharmaceutical Approaches in Dementia (2021) (16)
Treating status migrainosus in the emergency setting: what is the best strategy? (2018) (15)
Ipsilateral Alteration of Resting State Activity Suggests That Cortical Dysfunction Contributes to the Pathogenesis of Cluster Headache (2017) (15)
Effect of MPTP on mRNA expression of PGC-1α in mouse brain (2017) (15)
Phenoxybenzamine antagonizes somatostatin-induced antiamnesia in rats. (1984) (15)
Dissociation between Attentional Set Shifting and Habit Learning: a Longitudinal Case Study (2002) (15)
mRNA Expression Levels of PGC-1α in a Transgenic and a Toxin Model of Huntington’s Disease (2015) (15)
Clusterlike Headache as a First Sign of Brain Metastases of Lung Cancer (1996) (15)
Difference in white matter microstructure in differential diagnosis of normal pressure hydrocephalus and Alzheimer's disease (2016) (15)
APOE epsilon status in Hungarian patients with primary progressive multiple sclerosis. (2010) (15)
Macro- and microstructural alterations of the subcortical structures in episodic cluster headache (2018) (15)
Management of multiple sclerosis patients in central European countries: current needs and potential solutions (2018) (15)
Genetic polymorphisms of human β‐defensins in patients with ischemic stroke (2012) (15)
Glyceryl trinitrate treatment up-regulates soluble guanylyl cyclase in rat dura mater (2001) (14)
NMDA antagonists as Parkinson's disease therapy: disseminating the evidence. (2014) (14)
Effects of somatostatin-28 and some of its fragments and analogs on open-field behavior, barrel rotation, and shuttle box learning in rats (1990) (14)
Indoleamine 2,3-Dioxygenase Activity in Chlamydia muridarum and Chlamydia pneumoniae Infected Mouse Lung Tissues (2019) (14)
Speed or Accuracy Instructions During Skill Learning do not Affect the Acquired Knowledge (2020) (14)
Independent validation of Parkinson’s disease Sleep Scale 2nd version (PDSS-2) (2016) (14)
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease (2013) (14)
Somatosensory evoked potentials correlate with genetics in Huntington's disease (2002) (14)
Tumour necrosis factor alpha gene (TNF-α) −376 polymorphism in Hungarian patients with primary progressive multiple sclerosis (2009) (14)
Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid (2021) (14)
Lumbar cerebrospinal fluid concentrations of somatostatin and neuropeptide y in multiple sclerosis (1990) (14)
[The mechanism of peripheral and central sensitization in migraine. A literature review]. (2009) (13)
Mental disturbances in Parkinson's disease and related disorders: the role of excitotoxins. (2014) (13)
Influence of cysteamine and cysteine on open-field behaviour, and on brain concentrations of catecholamines, somatostatin, neuropeptide Y, and corticotropin releasing hormone in the rat (2005) (13)
Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase 1 Influenced the Age Onset of Parkinson's Disease. (2020) (13)
Simultaneous determination of 30 neurologically and metabolically important molecules: A sensitive and selective way to measure tyrosine and tryptophan pathway metabolites and other biomarkers in human serum and cerebrospinal fluid. (2020) (13)
Effects of cysteamine and pantethine on open-field behavior, hypothalamic catecholamine concentrations, and somatostatin-induced barrel rotation in rats (1989) (13)
Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013 (2016) (13)
Inhibition of opioid receptor mediated G-protein activity after chronic administration of kynurenic acid and its derivative without direct binding to opioid receptors. (2014) (13)
Epidemiology of multiple sclerosis in Central Europe, update from Hungary (2020) (13)
Kynurenines in the central nervous system: Recent developments (2007) (13)
Somatostatin28(15–28), but not somatostatin28(1–12), affects central monoaminergic neurotransmission in rats (1990) (13)
Recommendations for the Use of Prolonged‐Release Fampridine in Patients with Multiple Sclerosis (MS) (2013) (13)
HPLC method for the assessment of tryptophan metabolism utilizing separate internal standard for each detector. (2019) (13)
Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod. (2018) (13)
Relevance of defensin β-2 and α defensins (HNP1-3) in Alzheimer's disease (2016) (13)
Determination of binding capacity and adsorption enthalpy between Human Glutamate Receptor (GluR1) peptide fragments and kynurenic acid by surface plasmon resonance experiments. (2014) (13)
Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs (2014) (13)
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012–2015) (2016) (13)
Effects of Blood Glutamate Scavenging on Cortical Evoked Potentials (2010) (13)
Acetyl-l-carnitine restores synaptic transmission and enhances the inducibility of stable LTP after oxygen–glucose deprivation (2016) (12)
Genetic and molecular aspects of spinocerebellar ataxias (2005) (12)
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs (2020) (12)
Grey matter atrophy in patients suffering from multiple sclerosis. (2014) (12)
Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues (2016) (12)
Alpha-Tocopherol and NADPH in the Erythrocytes and Plasma of Multiple Sclerosis Patients (2003) (12)
Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease (2018) (12)
Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design. (2015) (12)
The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing (2015) (12)
Should magnesium be given to every migraineur? No (2012) (12)
Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions (2019) (12)
[The Multiple Sclerosis Registry of Szeged]. (2017) (11)
Alleviation of pain in painful diabetic neuropathy (2016) (11)
Modulatory effects of probenecid on the nitroglycerin-induced changes in the rat caudal trigeminal nucleus. (2009) (11)
Effect of subthalamic stimulation on distal and proximal upper limb movements in Parkinson's disease (2016) (11)
The effects of interaction between propranolol and somatostatin on the active avoidance behavior, open-field activity and electroconvulsive shock-induced amnesia of rats (1983) (11)
Prion diseases: New considerations (2016) (11)
Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy—Kynurenines Are Important Players (2021) (11)
Lack of age-related clinical progression in PGC-1α-deficient mice – implications for mitochondrial encephalopathies (2016) (11)
Gender-Specific Degeneration of Dementia-Related Subcortical Structures Throughout the Lifespan. (2016) (11)
Kynurenines in cognitive functions: their possible role in depression. (2012) (11)
The effect of orofacial complete Freund’s adjuvant treatment on the expression of migraine-related molecules (2019) (11)
Perceptual Categorization Is Impaired in Huntington’s Disease: An Electrophysiological Study (2003) (11)
Effects of Mitochondrial Toxins on the Brain Amino Acid Concentrations (2005) (11)
Comparative studies of intracerebroventricularly administered cysteamine and pantethine in different behavioral tests and on brain catecholamines in rats. (1990) (11)
Audio–visual integration through the parallel visual pathways (2015) (10)
Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects. (2017) (10)
Effects of valproate on the dopaminergic system in mice (2009) (10)
Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain (2020) (10)
Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient. (2006) (10)
Preparation and properties of nanoscale containers for biomedical application in drug delivery: preliminary studies with kynurenic acid (2012) (10)
Cognitive Functions in Ataxia with Oculomotor Apraxia Type 2 (2012) (10)
The effect of sleep deprivation on median nerve somatosensory evoked potentials (2005) (10)
Effect of probenecid on the pain-related behaviour and morphological markers in orofacial formalin test of the rat. (2015) (10)
Kynurenic Acid and Its Synthetic Derivatives Protect Against Sepsis-Associated Neutrophil Activation and Brain Mitochondrial Dysfunction in Rats (2021) (10)
Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors (2014) (10)
Distinct changes in chronic pain sensitivity and oxytocin receptor expression in a new rat model (Wisket) of schizophrenia (2020) (10)
P300 component of visual event-related potentials distinguishes patients with idiopathic Parkinson's disease from patients with essential tremor (2000) (10)
Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers (2021) (9)
NKX2-1 New Mutation Associated With Myoclonus, Dystonia, and Pituitary Involvement (2018) (9)
NEAT1 on the Field of Parkinson’s Disease: Offense, Defense, or a Player on the Bench? (2020) (9)
Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations (2019) (9)
SZR-104, a Novel Kynurenic Acid Analogue with High Permeability through the Blood–Brain Barrier (2021) (9)
Effect on memory processes of anti-vasopressin serum microinjected into the dorsal raphe nucleus: The role of catecholaminergic neurotransmission (1980) (9)
Structural Evaluation and Electrophysiological Effects of Some Kynurenic Acid Analogs (2019) (9)
Divergent Effects of the N-Methyl-D-Aspartate Receptor Antagonist Kynurenic Acid and the Synthetic Analog SZR-72 on Microcirculatory and Mitochondrial Dysfunction in Experimental Sepsis (2020) (9)
Sodium azide treatment decreases striatal and cortical concentrations of α-tocopherol in rats (2001) (9)
Neurological complications of pregnancy (1998) (9)
Needle in the brain (1996) (9)
Somatostatin and Alzheimer's disease. (1995) (8)
Kynurenic acid and its derivatives are able to modulate the adhesion and locomotion of brain endothelial cells (2018) (8)
Systemic administration of l-kynurenine sulfate induces cerebral hypoperfusion transients in adult C57Bl/6 mice. (2017) (8)
Postnatal outcome and placental blood flow after plasmapheresis during pregnancy (2016) (8)
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. (2008) (8)
An investigation of the white matter microstructure in motion detection using diffusion MRI (2014) (8)
Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects. (2019) (8)
[Paroxysmal kinesigenic dyskinesia]. (2011) (8)
Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose? (2020) (8)
[Botulinum neurotoxin--a therapy in migraine]. (2012) (8)
Gene variants and expression changes of SIRT1 and SIRT6 in peripheral blood are associated with Parkinson’s disease (2021) (8)
Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis (2021) (8)
High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. (2016) (8)
Cysteamine and pantethine effects on passive avoidance behavior, shuttle box learning, open-field activity, striatal catecholamines and somatostatin. (1989) (8)
Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain–Barré syndrome (2020) (8)
Kynurenic acid and its analogue can alter the opioid receptor G-protein signaling after acute treatment via NMDA receptor in rat cortex and striatum (2017) (8)
UVB irradiation-induced apoptosis increased in lymphocytes of Huntington's disease patients (2001) (8)
Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis (2017) (8)
Fiber density of the motor units recruited at high and low force output (2009) (8)
Trigeminal activation patterns evoked by chemical stimulation of the dura mater in rats (2020) (8)
The therapeutic impact of new migraine discoveries. (2019) (8)
Kynurenic Acid Analog Attenuates the Production of Tumor Necrosis Factor-α, Calgranulins (S100A 8/9 and S100A 12), and the Secretion of HNP1–3 and Stimulates the Production of Tumor Necrosis Factor-Stimulated Gene-6 in Whole Blood Cultures of Patients With Rheumatoid Arthritis (2021) (8)
The establishment of tocopherol reference intervals for Hungarian adult population using a validated HPLC method. (2017) (8)
Comparative studies with linear and cyclic somatostatin on the self-stimulation of rats. (1982) (8)
Suboccipital cerebrospinal fluid and plasma concentrations of corticotropin-releasings hormone and calcitonin gene-related peptide in patients with common migraine (1991) (7)
Correlation of neurochemical and imaging markers in migraine (2018) (7)
Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the ATP6V1B2 Gene (2020) (7)
Neurocognitive Characterization of an SCA28 Family Caused by a Novel AFG3L2 Gene Mutation (2017) (7)
Left ventricular deformation abnormalities in a patient with calpainopathy-a case from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path Study. (2017) (7)
The interaction between β-[Tyr9]melanotropin-(9–18), haloperidol and amphetamine in different behavior tests of rats (1982) (7)
Effect of a kynurenic acid analog on home-cage activity and body temperature in rats. (2015) (7)
Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies (2016) (7)
Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists (2020) (7)
Tryptophan Catabolites and Migraine. (2016) (7)
Kynurenic Acid and Its Analogs Are Beneficial Physiologic Attenuators in Bdelloid Rotifers (2019) (7)
Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy (2020) (7)
Selective decrease of hypothalamic noradrenaline by cysteamine. (1985) (7)
The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. (2016) (7)
Effect of somatostatin and its fragments on turning behaviour induced by unilateral substantia nigra lesion in the rat. (1984) (7)
Alzheimer's disease and somatostatin: A therapeutic hypothesis (1993) (7)
Effect of vinpocetine on retrograde axoplasmic transport. (2007) (7)
Genetic analysis of the SOD 1 and C 9 ORF 72 genes in Hungarian patients with amyotrophic lateral sclerosis (2017) (7)
Non-motor Behavioral Alterations of PGC-1α-Deficient Mice – A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression (2018) (7)
The effect of physical stimuli on the expression level of key elements in mitochondrial biogenesis (2019) (7)
Dose-related effects of cysteamine treatment on hypothalamic and striatal dopamine, noradrenaline and serotonin neurotransmission. (1985) (7)
Effects of pantethine, cysteamine and pantothenic acid on open-field behavior and brain catecholamines in rats. (1989) (7)
Kynurenines and Neurofilament Light Chain in Multiple Sclerosis (2021) (7)
Diverse effects of Brilliant Blue G administration in models of trigeminal activation in the rat (2015) (7)
Nitroglycerin increases serotonin transporter expression in rat spinal cord but anandamide modulated this effect (2017) (7)
CGRP and CGRP-receptor as targets of migraine therapy: Brain Prize-2021. (2021) (7)
Structural Magnetic Resonance Imaging Markers of Alzheimer's Disease and Its Retranslation to Rodent Models. (2015) (7)
The effect of "facteur thymique serique" (FTS) on catecholamine and serotonin neurotransmission in discrete brain regions of mice. (1987) (6)
Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma (2021) (6)
Disentangling competence from performance in behavioral measures of learning: A lesson for cognitive neuroscience (2019) (6)
Novel sequence variants of the alpha-galactosidase A gene in patients with Fabry disease. (2008) (6)
Pediatric multiple sclerosis and fulminant disease course: Features and approaches to treatment – A case report and review of the literature (2018) (6)
The effect of β-(Tyr9)melanotropin-(9–18) on active avoidance behavior, electroconvulsive shock-induced amnesia and T-discrimination learning of rats (1986) (6)
Association of cardiovascular risk factors and Parkinson's disease - case-control study in South East Hungary. (2018) (6)
Treatment With Pantethine (2011) (6)
Determination of binding capacity and adsorption enthalpy between Human Glutamate Receptor (GluR1) peptide fragments and kynurenic acid by surface plasmon resonance experiments. Part 2: Interaction of GluR1270-300 with KYNA. (2015) (6)
Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. (2013) (6)
Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up. (2006) (6)
Dose- and time-response effects of pantethine on open-field behavior, and on central neurotransmission in rats (1990) (6)
A novel SETX gene mutation producing ataxia with oculomotor apraxia type 2 (2016) (6)
Sensitivity of Rodent Microglia to Kynurenines in Models of Epilepsy and Inflammation In Vivo and In Vitro: Microglia Activation Is Inhibited by Kynurenic Acid and the Synthetic Analogue SZR104 (2020) (6)
[Kynurenine and its metabolites in nervous system diseases]. (1992) (6)
Chronic 17β-estradiol pretreatment has pronociceptive effect on behavioral and morphological changes induced by orofacial formalin in ovariectomized rats (2018) (6)
B7 costimulation and intracellular indoleamine 2,3-dioxygenase expression in umbilical cord blood and adult peripheral blood. (2014) (6)
Proteomics in Multiple Sclerosis: The Perspective of the Clinician (2022) (6)
A rare manifestation of Fabry's disease. (2007) (5)
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on passive and active avoidance behavior and on open-field activity of rats (1982) (5)
Effects of β-/Tyr9/melanotropin-/9–18/ on apomorphine-induced stereotyped cage-climbing and on striatal dopamine release in mice. Comparative studies with amphetamine (1982) (5)
International Headache Society abstracts (2015) (5)
Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials (2021) (5)
Adverse effects of dopamine potentiation by long‐term treatment with selegiline (2004) (5)
Chemokine receptor V Δ32 deletion in multiple sclerosis patients in Csongrád County in Hungary and the North-Bácska region in Serbia. (2015) (5)
[Current data on the pathogenesis of neurodegenerative diseases and some muscular disorders: therapeutic prospectives]. (1993) (5)
The detection of age-, gender-, and region-specific changes in mouse brain tocopherol levels via the application of different validated HPLC methods (2018) (5)
A simple novel technique to induce short‐lasting local brain ischaemia in the rat (2014) (5)
Behavioral and pharmacological effects of centrally administered aminooxyacetic acid in rats. (1992) (5)
[The modulatory effect of estrogen on the caudal trigeminal nucleus of the rat in an animal model of migraine]. (2006) (5)
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment? (2022) (5)
Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntington’s Disease (2020) (5)
Fixed-dose combination therapy for Parkinson’s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime (2020) (5)
Neuroborreliosis in county Baranya, Hungary. (1998) (5)
OLD AND NEW NEUROENDOCRINE MOLECULES: SOMATOSTATIN, CYSTEAMINE, PANTETHINE AND KYNURENINE. (2014) (5)
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations (2022) (5)
Familial multiple sclerosis: case study of three affected siblings (2002) (5)
Modelling and Characterization of the Sorption of Kynurenic Acid on Protein Surfaces (2017) (5)
[Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders]. (2003) (5)
Promising therapeutic agents for the treatment of Parkinson’s disease (2016) (5)
Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine. (2019) (4)
Acetyl-L-carnitine and oxaloacetate in post-treatment against LTP impairment in a rat ischemia model. An in vitro electrophysiological study (2015) (4)
Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part II: Potential causes and laboratory tests. (2013) (4)
Impaired language production in asymptomatic carotid stenosis (2013) (4)
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System. (2016) (4)
The Effect of Emotion and Reward Contingencies on Relational Memory in Major Depression: An Eye-Movement Study with Follow-Up (2016) (4)
[The carrier model of neurology in Hungary: a proposal for the solution until 2020]. (2011) (4)
The effects of β-(TYR9)melanotropin-(9–18) and H-PHE-ILE-TYR-HIS-SER-TYR-LYS-OH on the analgesic action of morphine (1983) (4)
Deepening understanding of the neural substrates of chronic pain (2014) (4)
VALIDATION OF THE HUNGARIAN UNIFIED DYSKINESIA RATING SCALE (2015) (4)
Lateral Interactions and Speed of Information Processing in Highly Functioning Multiple Sclerosis Patients (2007) (4)
Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias. (2019) (4)
Az egységesített dyskinesia-pontozóskála magyar nyelvi validációja (2015) (4)
CANOMAD syndrome with respiratory failure. (2020) (4)
Effect of intracerebroventricular administration of β-/Tyr9/-melanotropin-/9–18/ on rotational behavior induced by substantia nigra lesion in rats (1983) (4)
Pharmacological models of Parkinson's disease in rodents. (2011) (4)
Corrigendum to “Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans” [J. Neuroimmunol. 179 (2006) 108–116] (2007) (4)
[VALIDATION OF THE HUNGARIAN UNIFIED DYSKINESIA RATING SCALE]. (2015) (4)
Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson’s disease patients (2019) (4)
A New Division of Schizophrenia Revealed Expanded Bilateral Brain Structural Abnormalities of the Association Cortices (2017) (4)
Neurology training around the world: asking the trainees (2010) (4)
Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase Influenced the Age Onset of Parkinson’s Disease (2020) (4)
Long-term systemic administration of kynurenic acid brain region specifically elevates the abundance of functional CB1 receptors in rats (2020) (4)
Diffusion MRI measured white matter microstructure as a biomarker of neurodegeneration in preclinical Huntington's disease. (2013) (3)
[Zonisamide treatment in myoclonus-dystonia]. (2019) (3)
[Complementary therapies--based on the principles of evidence-based medicine. Position statement of the Medical Sciences Section of the Hungarian Academy of Sciences]. (2011) (3)
Antidepressant-like Effects of Kynurenic Acid Analogues (2021) (3)
The Role of the Kynurenine Pathway in Neurodegenerative Diseases (2015) (3)
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms (2022) (3)
Gray Matter Atrophy to Explain Subclinical Oculomotor Deficit in Multiple Sclerosis (2019) (3)
Correlation of neurochemical and imaging markers in AU 1 migraine PACAP 38 and DTI measures (2018) (3)
[Molecular pathology and clinical manifestations of Fabry disease]. (2007) (3)
Editorial: Multiple Implications of the Kynurenine Pathway in Inflammatory Diseases: Diagnostic and Therapeutic Applications (2022) (3)
Research report Electrophysiological correlates of visual categorization: evidence for cognitive dysfunctions in early Parkinson's disease (2002) (3)
Therapeutic strategies that act on the peripheral nervous system in primary headache disorders (2019) (3)
Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases? (2012) (3)
Skill learning can be independent of speed and accuracy instructions (2019) (3)
IRS 2 Insulin receptor substrate-2 (2017) (3)
Predominant neurological phenotype in a Hungarian family with two novel mutations in the XPA gene—case series (2019) (3)
Az MRI helye a sclerosis multiplex kezelés hatékonyságának megítélésében II.: mérési protokollok (2018) (3)
A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia (2021) (3)
[Clinical symptoms, diagnosis and treatment of focal dystonias]. (2001) (3)
Comparative studies with beta-(Tyr9)melanotropin-(9-18) and amphetamine on open-field behavior and striatal dopamine uptake and release. (1984) (3)
[Glycolytic enzyme defects and neurodegeneration]. (1998) (3)
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. (2017) (3)
Effects of interrupted immunomodulant therapy on the neurological state of multiple sclerosis patients (2007) (3)
[Clinical studies with levodopa/carbidopa intestinal gel]. (2014) (3)
Peripheral kynurenine metabolism in focal dystonia. (2007) (3)
Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson’s disease (2021) (2)
[The significance of Chlamydia pneumoniae in selected neurologic disorders]. (2006) (2)
Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part I: Concept of resistance. (2012) (2)
Functional morphology in pre-symptomatic Huntington’s Disease : evidence from Hungarian (2008) (2)
Endovascular thrombolytic treatment of extensive dural sinus thrombosis in a heterozygous carrier of prothrombin gene G20210A mutation (2004) (2)
The assessment of possible gender-related effect of endogenous striatal alpha-tocopherol level on MPTP neurotoxicity in mice (2020) (2)
Possible role of the basal ganglia in the generation of the N30 potential of the median nerve somatosensory evoked potentials. (2007) (2)
[The role of MRI in measuring the effectivity of disease modifying treatments II]. (2018) (2)
The effect of psychiatric comorbidities and stress-coping strategies on perceived quality of life in migraine. (2019) (2)
[Endangered future: education and replacement of specialists in neurology--a survey in Hungary, 2010]. (2010) (2)
Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress (2022) (2)
[Comparative study of novel therapeutic possibilities in animal experimental model of inflammatory bowel disease]. (2012) (2)
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM. (2015) (2)
[Haemodynamic instability induced by carotid stent implantation]. (2006) (2)
The first identified Central-Eastern European patient with genetically confirmed dentatorubral-pallidoluysian atrophy. (2015) (2)
Brain MRI Diffusion Encoding Direction Number Affects Tract‐Based Spatial Statistics Results in Multiple Sclerosis (2020) (2)
[Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism]. (2012) (2)
Action of Hypothalamic Heptapeptide (H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH) on the Central Nervous System (1987) (2)
Kynurenic Acid and Its Analog SZR104 Exhibit Strong Antiinflammatory Effects and Alter the Intracellular Distribution and Methylation Patterns of H3 Histones in Immunochallenged Microglia-Enriched Cultures of Newborn Rat Brains (2022) (2)
Species-specific neuronal localization of kynurenine aminotransferase-2 in the mouse cerebellum (2020) (2)
[The role of MRI in measuring the effectivity of disease modifying treatments I]. (2018) (2)
Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients. (2022) (2)
[Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary]. (2014) (2)
The Report of p.Val717Phe Mutation in the APP Gene in a Hungarian Family With Alzheimer Disease: A Phenomenological Study. (2017) (2)
New Therapies for Treating Early Parkinson’s Disease (2010) (2)
[Statin drugs decrease the plasma level of coenzyme Q10 (ubiquinone) in the organism]. (2007) (2)
GENETIC POLYMORPHISMS OF HUMAN β-DEFENSINS IN PATIENTS WITH MULTIPLE SCLEROSIS. (2015) (2)
Established therapies and novel targets in the treatment of Parkinson’s disease (2009) (2)
[Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease]. (2007) (2)
Sodium azide treatment decreases striatal and cortical concentrations of alpha-tocopherol in rats. (2001) (2)
[Long term experience with Stalevo in Szeged, Hungary]. (2009) (2)
Kynurenines and the nervous system: therapeutic perspectives (2012) (2)
mRNA Expression Levels of PGC-1α in a Transgenic and a Toxin Model of Huntington’s Disease (2014) (2)
The role of central dopaminergic systems in the behavioral effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH (1985) (2)
Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. (2019) (2)
Do Hungarian multiple sclerosis care units fulfil international criteria? (2022) (2)
Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease (2020) (2)
Shapiro-szindróma, azaz a termoregulációs zavar ritka esete (2016) (2)
EEG spectral changes induced by hemodialysis (2021) (2)
Evaluation of white matter alterations in Alzheimer's disease and normal pressure hydrocephalus as measured by diffusion weighted MRI (2012) (2)
Concentration- and time-dependent effect of aminooxyacetic acid on cortical epileptogenicity. (2002) (2)
Effects of Short- and Long-Term Stimulation of the Gasserian Ganglion on the Cgrp Innervation Pattern of the Cerebral Dura Mater (1995) (1)
Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in advanced Parkinson's disease (2017) (1)
Neurogenic Inflammation: One of the Participants of Migraine and the Contribution of Translational Research (2021) (1)
P.5.d.008 Ten-day cognitive training program combined with transcranial direct current stimulation (tDCS) in stroke rehabilitation – a sham controlled study (2017) (1)
Gray matter atrophy in presymptomatic Huntington's patients. (2016) (1)
A relapszus-remisszio korformaju sclerosis multiplex kezelese (1998) (1)
Effects of 3-aminopyridine-induced seizures on platelet eicosanoid synthesis. (2008) (1)
[New data for the pathomechanism of neuropathic pain: therapeutic evidences]. (2013) (1)
Predicting multiple sclerosis: a large international multicentre study (2015) (1)
Parkinson’s disease: will therapy move beyond dopaminergic medication? (2011) (1)
Distinct cytokine patterns may regulate the severity of neonatal asphyxia—an observational study (2017) (1)
Neurology in Hungary: Past, present, and future (2013) (1)
How to minimize the risk for headache? A lumbar puncture practice questionnaire study. (2016) (1)
Is diffusion magnetic resonance imaging the future biomarker to measure therapeutic efficacy in multiple sclerosis? (2018) (1)
Recent advances in Parkinson's disease. (2002) (1)
Effect of kynurenic acid on sensitivity to cortical spreading depression in rats (2010) (1)
Book review – Announcements (2001) (1)
Neuroprotective effects of repeated transient global ischemia and of kynurenine adminsitration induced by four-vessel occlusions on hippocampal CA1 neurons. (2007) (1)
AZ IDEGRENDSZERI EXCITOTOXINOK PATOLOGIAI ES KLINKAI JELENTOSEGE. II. RESZ. AZ ISCHAEMIA CELLULARIS KOVETKEZMENYEI. A KRONIKUS NEURODEGENERACIO, A BEFOLYASOLAS LEHETOSEGEI (1998) (1)
The Effects of Bilateral Theta-burst Stimulation on Executive Functions and Affective Symptoms in Major Depressive Disorder (2021) (1)
Radio-neuroprotective effect of a phosphatidylcholine derivative in a rat model of irradiation (2013) (1)
Is Ro 61-8048 a potential fast-acting antidepressant? (2012) (1)
Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat (2012) (1)
The genetic background of Parkinson’s disease and novel therapeutic targets (2022) (1)
Az mri helye a sclerosis multiplex kezelés hatékonyságának megítélésében I.: Mérési markerek (2018) (1)
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists. (2008) (1)
A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report. (2020) (1)
First data from constraint induced aphasia therapy for Hungarian patients (2013) (1)
LOCALLY INJECTED ANTI-VASOPRESSIN SERUM AND PASSIVE AVOIDANCE BEHAVIOR: THE ROLE OF CATECHOLAMINERGIC NEUROTRANSMISSION+ (1981) (1)
[Advanced Parkinson's disease characteristics in clinical practice: Results from the OBSERVE-PD study and sub-analysis of the Hungarian data]. (2020) (1)
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on the in vitro uptake and release of radiolabelled dopamine, noradrenaline and serotonin in rat brain hypothalamic slices (1984) (1)
Relationships of Ischemic Stroke Occurrence and Outcome with Gene Variants Encoding Enzymes of Tryptophan Metabolism (2021) (1)
Wisket rat model of schizophrenia: Impaired motivation and, altered brain structure, but no anhedonia (2021) (1)
Data from: Correlation of neurochemical and imaging markers in migraine PACAP38 and DTI measures (2018) (1)
Columnar organization of nitric oxide synthase (NOS) in the prefrontal cortex of primates. (1999) (1)
[Treatment of relapsing-remitting multiple sclerosis with interferon beta type 1-b]. (1999) (1)
Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain (2023) (1)
ÖSSZEFOGLALÓ KÖZLEMÉNY CURRENT MEDICAL ASPECTS OF PANTETHINE Treatment strategies (2009) (1)
Cerebrovascular Complications and Polycythaemia Vera (2019) (1)
Lateralisation of the white matter microstructure associated with the hemispheric spatial attention dominance (2019) (1)
The role of cognitive training in the neurorehabilitation of a patient who survived a lightning strike. A case study. (2014) (1)
[Endangered future: education and replacement of specialists in neurology--a survey, 2010]. (2010) (1)
Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance (2021) (1)
[Clinical features and diagnosis of spinocerebellar ataxia]. (2004) (1)
[TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS]. (2015) (1)
[Inclusion body myositis--a rarely recognized disorder]. (2013) (1)
[Clinical studies on pramipexol retard]. (2010) (1)
Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: a model-free analysis approach (2021) (1)
[Multiple ischemic stroke in Osler-Rendu-Weber disease]. (2019) (1)
Paradox effects of kynurenines on LTP induction. An in vivo study in the Wistar rat. (2015) (1)
[Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders]. (2000) (1)
[A rare case of thermoregulation disorder: Shapiro syndrome]. (2016) (1)
AZ IDEGRENDSZERI EXCITOTOXINOK PATOLOGIAI ES KLINIKAI JELENTOSEGE (1998) (1)
A Parkinson-kor stadiumbeosztasa es az elorehaladott stadium kezelesenek nehany aktualis problemaja (2018) (0)
[Change of therapeutic algorithm in sclerosis multiplex based on two case reports]. (2017) (0)
Kynurenic acid and its novel analogue SZR-72 attenuate the severity of experimental acute necrotizing pancreatitis (2015) (0)
Corrigendum to “Migraine and neuropeptides” [Neuropeptides (2015) 19–30] (2016) (0)
[Natural killer cell activity in multiple sclerosis patients]. (1997) (0)
[Current questions of multiple sclerosis: the secunder progressive form of the disease]. (2020) (0)
Chapter 16. Mild Traumatic Brain Injury (2008) (0)
Az akut vascularis képalkotás és a neurointervenció igénybevétele akut ischaemiás stroke betegeknél Magyarországon (2019) (0)
P.301 Bilateral theta-burst stimulation improves affective symptoms but not executive functions in major depressive disorder (2021) (0)
The use of transcranial direct current stimulation in stroke rehabilitation: effects on mood and cognition (2019) (0)
Utilization of acute vascular imaging and neurointervention for acute ischaemic stroke patients in 20 Hungarian stroke centers. (2019) (0)
Rare co-occurrence of multiple sclerosis and Wilson’s disease – case report (2022) (0)
[Report from the 2011 scientific meeting of the Környey Society. Part 1]. (2011) (0)
Contents Vol. 16, 2003 (2003) (0)
[Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy]. (2017) (0)
Kynurenic acid and kynurenine aminotransferase are potential biomarkers of early neurological improvement after thrombolytic therapy: A pilot study. (2021) (0)
Integrative assessment of brain atrophy in Alzheimer's disease: Parallel hippocampal and thalamic atrophy (2012) (0)
EPA-0381 – Preliminary Studies on Cerebrospinal Fluid of Patient with Alzheimer's Disease Using Peptide Microarray (2014) (0)
1.319 Effects of valproate on dopaminergic system in mice (2007) (0)
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on different behavioral tests of rats (1985) (0)
24-Hour Near-Infrared Spectroscopy Monitoring of Acute Ischaemic Stroke Patients Undergoing Thrombolysis or Thrombectomy: A Pilot Study. (2019) (0)
Kynurenic acid and its novel analogue SZR-72 ameliorate experimental acute necrotizing pancreatitis (2017) (0)
Idegi plaszticitás és neuroprotekció lehetőségeinek kutatása triptofán metabolitokkal és származékaikkal = Neuronal plasticity and neuronal protection - research with triptophan-metabolites and conjugates (2008) (0)
The effects of different receptor blockers on the H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH induced inhibition of extinction of active avoidance behaviour. (1988) (0)
Kinureninek és gyógyszerkutatás (2020) (0)
Légzési elégtelenséggel járó CANOMAD szindróma (2020) (0)
Action of β-(Tyr9)melanotropin-(9–18) on the Central Nervous System (1987) (0)
A kinureninrendszer és a stressz (2015) (0)
A comparative value of T 1 and T 2-weighted magnetic resonance imaging ( MRI ) and transcranial sonography ( TCS ) in Parkinson ’ s disease : a prospective pilot study of 16 cases (2014) (0)
A kinureninrendszer és a stressz (2015) (0)
Creatine treatment to relieve muscle pain caused by thyroxine replacement therapy. (2012) (0)
EHMTI-0189. Tryptophan-kynurenine metabolism in migraine patients (2014) (0)
The clinical manifestations of two novel SPAST mutations (2015) (0)
Cluster headache and kynurenines (2023) (0)
L13 Stimulation of the PGC-1A expression in mouse brain (2016) (0)
Epidemiologic characteristics of a Hungarian subpopulation of Huntington’s Disease patients (2020) (0)
Correlation between blood pressure and the level of monoamines in the cerebrospinal fluid of patients with cerebral haemorrhage. Case reports. (1987) (0)
Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntington’s disease (2021) (0)
Unilateral thalamic infarction causing downward gaze palsy in a patient with uncorrected tetralogy of fallot: a case report. (2016) (0)
[Editorial commentary. Hans Selye Symposium, Budapest, November 2014]. (2015) (0)
The Tryptophan-Kynurenine Metabolic System Is Suppressed in Cuprizone-Induced Model of Demyelination Simulating Progressive Multiple Sclerosis (2023) (0)
Long-term effects of lithium on receptor-mediated inositol lipid metabolism (1990) (0)
A tau fehérje meghatározás kiegészítő szerepe a Creutzfeldt-Jakob-betegség diagnosztikájában (2019) (0)
Corrigendum: The Effect of Systemic Nitroglycerin Administration on the Kynurenine Pathway in the Rat (2020) (0)
New trends in classification, monitoring and management of neurological diseases (2003) (0)
Aspirin and Clopidogrel Resistance (2004) (0)
Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (2019) (0)
Neurocognitive Characterization of an SCA28 Family Caused by a Novel AFG3L2 Gene Mutation (2017) (0)
[B-cell depletion in the therapy of mulitple sclerosis: ofatumumab is a new player]. (2022) (0)
[Alemtuzumab therapy 2017]. (2017) (0)
Frontiers in Clinical Neuroscience (2004) (0)
The role of the nucleus accumbens septi (NAS) in the behavioral action of β-(Tyr9)melanotropin-(9–18) (1985) (0)
Mágnesesrezonancia-képalkotas alemtuzumab- és teriflunomidkezelés során (2017) (0)
Homoplastic A12,753G mitochondrial DNA mutation in a Hungarian family (1998) (0)
Author's response to Letter to the Editor by Kauffman et al. published in JNI 212/1–2, June 2009 (2009) (0)
Spreading depression and evoked potentials recorded in the somatosensory cortex of the rat (2010) (0)
Fejfájás • Headache (2023) (0)
Male brain ages faster: the age and gender dependence of subcortical volumes (2015) (0)
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review (2023) (0)
The Kynurenic Acid Analog SZR72 Enhances Neuronal Activity after Asphyxia but Is Not Neuroprotective in a Translational Model of Neonatal Hypoxic Ischemic Encephalopathy (2021) (0)
Reviewer acknowledgment 2017 (2017) (0)
Unaltered mRNA expression of calcitonin-like receptor and receptor activity modifying proteins in human arteries in stroke and myocardial infarction. (2007) (0)
AB0107 INVESTIGATION OF THE EFFECTS OF KYNURENIC ACID ANALOGS IN RHEUMATOID ARTHRITIS (2020) (0)
Beta-interferon effects the tryptophan metabolism in the plasma of multiple sclerosis patients (2004) (0)
Astrocytic and neuronal localization of kynurenine aminotransferase-2 in the adult mouse brain (2016) (0)
Kynurenines and neuroprotection (2009) (0)
Correction to: Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy (2020) (0)
Interaction of vasopressin, oxytocin and the cerebral catecholaminergic system in active avoidance behaviour in rats (1978) (0)
[Natalizumab in multiple sclerosis]. (2008) (0)
The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary (2022) (0)
S145 Investigating the kynurenine pathway in a novel – In vitro – Model: Possibility for simultaneous biochemical, histological and electrophysiological assessments (2017) (0)
Kynurenic acid decreases sensitivity to cortical spreading depression in rat (2010) (0)
[The treatment of advanced Parkinson's disease]. (2018) (0)
Cerebrospinal fluid proteome analysis reveals differentially abundant proteins in multiple sclerosis (2014) (0)
REMOVED: Paradox effects of kynurenines on LTP induction. An in vivo study in the Wistar rat (2015) (0)
A spinocerebellaris ataxiák klinikuma és diagnosztikája. (2004) (0)
The role of neurotransmitters in mediating the effect of somatostatin on self-stimulation behavior in rats (1989) (0)
Expert Opinion on Biological Therapy (2016) (0)
HYPERGLYCAEMIC HEMIBALLISMUS: IMPLICATIONS FROM CONNECTIVITY ANALYSIS FOR COGNITIVE IMPAIRMENTS. (2015) (0)
A novel SETX gene mutation producing ataxia with oculomotor apraxia type 2 (2016) (0)
Headache: Diagnosis and Treatment (1958) (0)
Connection between small vessel disease related stroke and the MTHFR C677T polymorphism in a Hungarian population (2020) (0)
[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities]. (1997) (0)
P.401 Online theta-range transcranial alternating current stimulation results in slower conflict processing (2020) (0)
The Role of Kynurenine Pathway in Pain and Migraine (2015) (0)
WHICH IS THE BETTER DOPAMINOMETIC THERAPY FOR PD? ORAL (2012) (0)
Kynurenic acid and its novel analogue SZR-72 ameliorate experimental acute necrotizing pancreatitis in rats via NMDA-1 receptor (2018) (0)
Meetings, Symposia – Organized under the auspices of the International Danube Neurology Association (2006) (0)
Neuroprotection by kynurenine metabolites (2014) (0)
Alemtuzumabterápiával kezelt sclerosis multiplexes betegek követéses vizsgálata a szegedi Sclerosis Multiplex Centrumban (2022) (0)
Estradiol Treatment Enhances Behavioral and Molecular Changes Induced by Repetitive Trigeminal Activation in a Rat Model of Migraine (2022) (0)
Új adatok a neuropátiás fájdalom patomechanizmusához: Terápiás evidenciák (2013) (0)
Are we minimizing the patients' risk for headache? : a lumbar puncture practice questionnaire study among European neurologists (2015) (0)
Subject Index Vol. 50, 2003 (2003) (0)
Szklerózis multiplex • Multiple Sclerosis (2023) (0)
Revisiting the observation of anxiety-like behavior and assessing phenotypic progression in PGC-1α-deficient mice (2013) (0)
[Chronic inflammatory polyneuropathies]. (2005) (0)
Into the Masseter Muscle Afferent Discharge Evoked by Injection of Glutamate Sex-Related Differences in Human Pain and Rat (2015) (0)
Independent validation of Parkinson’s disease Sleep Scale 2nd version (PDSS-2) (2015) (0)
Az előrehaladott Parkinson-kór jellemzői a klinikai gyakorlatban: az OBSERVE-PD vizsgálat eredményei és a magyarországi alcsoport elemzése (2020) (0)
A relapsus-remissio kórformájú sclerosis multiplex kezelése immunglobulinnal (2003) (0)
[Stress and the kynurenine pathway]. (2015) (0)
Kynurenine administration suppresses cortical spreading depression in rat and the effect size is sex hormone dependent (2011) (0)
ID 395 – Effect of transcranial direct stimulation on pseudo-neglect in healthy subjects: Results of a pilot study (2016) (0)
MEGHATÁROZÁSA CREUTZFELDT-JAKOB BETEGEKNEL THE ASSESSMENT OF CONCENTRATIONS OF CERTAIN TRYPTOPHAN METABOLITES IN CREUTZFELDT-JAKOB DISEASE (2018) (0)
DANUBE NEUROLOGY NEWSLETTER (2006) (0)
Constraint-Induced Linguistic Therapy for Aphasic Patients in Hungary (2015) (0)
Therapeutic approaches in stroke (1995) (0)
The detection of age-, gender-, and region-specific changes in mouse brain tocopherol levels via the application of different validated HPLC methods (2018) (0)
Terápiás algoritmus változása sclerosis multiplexben két esettanulmány alapján (2017) (0)
P297 Atypical carpal tunnel syndrome caused (mimicked) by bifid median nerve (2017) (0)
The effect of beta-(Tyr9)melanotropin-(9-18) on the active avoidance and open-field behavior on rats pretreated with atropine or propranolol. (1984) (0)
Zonisamidkezelés myoclonusdystoniában (2019) (0)
[Follow up examination of multiple sclerosis patients treated with alemtuzumab in Multiple Sclerosis Centre, Szeged]. (2022) (0)
[Pseudosyncope and pseudoseizure]. (2007) (0)
Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study (2022) (0)
S147 Imaging biomarkers of primary headache disorders (2017) (0)
[Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis]. (2006) (0)
The novel kynurenin analogue SZR-72 reduces the severity of acute pancreatitis in rats (2014) (0)
Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants. (2022) (0)
Neuroprotekciós beavatkozásások globális ischemia modelleken: a stroke megelőzésének és terápiájának egy új megközelítése = Neuroprotective interventions on models of the global ischemia: a new approach for prevention and therapy of stroke (2013) (0)
Crosstalk between Existential Phenomenological Psychotherapy and Neuroscience in Mood and Anxiety Disorders (2020) (0)
A sclerosis multiplex néhány aktuális kérdése: a szekunder progresszív forma (2020) (0)
A Wall Street Journal ismerteti a Szegedi neurológusok és pszichológusok tanulmányát (2013) (0)
[Ophthalmoplegia in herpes zoster: clinical review based on two case reports]. (1993) (0)
Contents Vol. 50, 2003 (2003) (0)
Kynurenic Acid and Its Analogue SZR-72 Ameliorate the Severity of Experimental Acute Necrotizing Pancreatitis (2021) (0)
Increased PPAR-gamma levels in the CSF of patients with multiple sclerosis (2013) (0)
Can somatosensory evoked potentials predict disease course in early multiple sclerosis patients? (2013) (0)
FP04-MO-02 European residency training (2009) (0)
Protein Misfolding, Mitochondrial Disturbances, And Kynurenines In The Pathogenesis Of Neurodegenerative Disorders (2010) (0)
Non-specific peroxidase (donor: H2O2-oxidoreductase, EC 1.11.1.7) activity in multiple sclerosis. (1990) (0)
Triptofán és bizonyos metabolitjainak koncentrációjának meghatározása Creutzfeldt-Jakob betegeknél (2017) (0)
[The Wall Street Journal's report about the study of neurologists and psychologists from Szeged]. (2013) (0)
Novel preclinical therapeutic strategies of neurodegeneration with kynurenines: Clinical perspectives (Danube Neurology Session) (2013) (0)
Contents Vol. 12, 2013 (2013) (0)
Bevezető • Introduction (2023) (0)
Experiences with interferon-beta-1b treatment in MS after three year follow-up. (2002) (0)
Frontiers in clinical neuroscience : neurodegeneration and neuroprotection : a symposium in Abel Lajtha's honour (2004) (0)
Extrapiramidális kórképek • Movement Disorders (2023) (0)
Correlation between monoamine content and other parameters of cerebrospinal fluid in aneurysmal subarachnoid haemorrhage: a case report. (1986) (0)
Low dosage of rimonabant leads to anxiolytic like behavior in a cannabinoid receptor independent manner via inhibiting expression levels and G-protein activity of kappa opioid receptors (2015) (0)
[Controversies in neurology: Diagnosis, follow up and therapy of multiple sclerosis with pathomechanismal approach]. (2021) (0)
B-sejt-depletio a sclerosis mulitplex terápiájában: új szereplő az ofatumumab (2022) (0)
Ellentmondások a neurológiában: A sclerosis multiplex diagnózisának, követésének és terápiájának aktuális kérdései a patomechanizmus megközelítésével (2021) (0)
Ipsilateral Alteration of Resting State Activity Suggests That Cortical Dysfunction Contributes to the Pathogenesis of Cluster Headache (2016) (0)
E-vitamin mérésre alkalmas nagyhatékonyságú folyadékkromatográfiás módszerek fejlesztése és validálása (2017) (0)
A kinureninek és a kognitív funkció összefüggései, és lehetséges szerepük a depresszió kialakulásában (2012) (0)
Kynurenic acid analogue SZR-72, but not SZR-73, SZR-81 and SZR-104 treatment moderates the severity of acute necrotizing pancreatitis in rats (2019) (0)
Hot Water and Glycerol Treatment of the Gasserian Ganglion: Effects Upon the Innervation Pattern of the Cerebral Dura Mater and the Caudal Trigeminal Nucleus (1995) (0)
Kynurenic acid is able to suppress cortical spreading depression and the effect size is sex hormone dependent (2011) (0)
KÖZLEMÉNY CAN SOMATOSENSORY EVOKED POTENTIALS PREDICT DISEASE COURSE IN EARLY MULTIPLE SCLEROSIS PATIENTS ? (2013) (0)
Subject Index Vol. 16, 2003 (2003) (0)
Response (2009) (0)
CHAPTER 14:Tryptophan Metabolism in Parkinson’s Disease: Future Therapeutic Possibilities (2013) (0)
A Levodopa/Carbidopa intestinalis gél kezelés magyarországi tapasztalatai elorehaladott parkinson-kórban (2014) (0)
[Kynurenines and drug research]. (2020) (0)
Terápiás lehetőségek a gyulladásos bélbetegség állatkísérletes modelljében – összehasonlító vizsgálat (2012) (0)
Sodium lactate differently alters relative EEG power in Alzheimer's disease' brain (2009) (0)
TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine (2022) (0)
Vascular depression and vascular cognitive impairment share some common pathological aspects Citalopram can be useful in the treatment of vascular depression (2009) (0)
Meet Our Editorial Board Member (2020) (0)
Subject Index Vol. 46, 2001 (2001) (0)
[[Natalizumab therapy, 2013]. (2014) (0)
Long-term effect of immunization with neural and nonneural antigens on the noradrenaline and serotonin levels of discrete brain areas in mice and the relationship between neurotransmitter levels and antibody production. (1991) (0)
Contents Vol. 46, 2001 (2001) (0)
Continuous theta-burst stimulation over the dorsolateral prefrontal cortex inhibits improvement on a working memory task (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With László Vécsei?

László Vécsei is affiliated with the following schools:

László Vécsei's Academic­Influence.com Rankings